Form 4: Ventyx Biosciences CEO Acquires 116,668 Shares Through RSU Vesting

Ventyx Biosciences CEO, Raju Mohan, acquired 116,668 shares of common stock through the vesting of restricted stock units.

Summary

• Raju Mohan, CEO and President of Ventyx Biosciences, acquired 116,668 shares of common stock.
• The acquisition occurred on December 17, 2024, through the vesting of restricted stock units (RSUs).
• These RSUs were part of an award that vests over four years, with 25% vesting on each anniversary of the Vesting Commencement Date, which was December 17, 2021.
• The price per share for the acquisition was $0, as it was a vesting event, not a purchase.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. It is a positive sign that the CEO is meeting the vesting requirements, but it is not a major event that would significantly impact the company's outlook.

Positives

• The vesting of RSUs indicates that the CEO is meeting the conditions of his equity incentive plan.
• The acquisition of shares through vesting aligns the CEO's interests with those of the shareholders.

Industry Context

This is a standard transaction for executives who receive equity compensation as part of their overall package. It is common for companies to use RSUs as a way to align management's interests with those of shareholders.

Comparison to Industry Standards

• The vesting schedule of 25% per year is a common practice in the biotechnology industry for RSU grants.
• Many comparable companies use similar equity compensation plans to incentivize their executives.
• The use of RSUs is a standard method for aligning executive compensation with long-term company performance.

Stakeholder Impact

• The vesting of RSUs has a minor positive impact on shareholders as it aligns the CEO's interests with the company's long-term performance.

Key Dates

Keywords

Ventyx Biosciences, Raju Mohan, restricted stock units, RSU, stock vesting, equity compensation, CEO, insider transaction